首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Antibodies against beta-fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients.
【24h】

Antibodies against beta-fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients.

机译:针对β-纤维蛋白合成肽的抗体:类风湿关节炎患者免疫原性背景和疾病进程的研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Preliminary studies have shown the potential application for the diagnosis of Rheumatoid Arthritis (RA) patients with a severe disease course of an epitopic domain of beta-fibrin. The aim of the present work was the analysis of the presence of antibodies against several beta-fibrin synthetic peptides in relation to the immunogenetic background and disease course in a clinically well-defined RA patient cohort. Our results indicated that positive patients against anti-beta-fibrin synthetic peptides have a higher percentage of HLA-DRB1 shared epitope (SE) than negative patients. We also observed that the presence of SE alleles was significantly associated with a higher level of anti-[Cit(376)]betafib(365-383) antibodies. When analyzing the effect of different SE alleles, we found a significant positive association between carriers of QRRAA allele and [Cit(376)]betafib(365-383) (Odds ratio 3.77; CI95%: 1.41-10.08). These results suggest that the anti-beta-fibrin status is associated with the immunogenetic background of RA patients.
机译:初步研究表明,该疾病可用于诊断风湿性关节炎(RA)伴有β-纤维蛋白表位域严重疾病的患者。本工作的目的是在临床上明确定义的RA患者队列中,针对几种β-纤维蛋白合成肽的抗体与免疫遗传背景和疾病进程的关系进行分析。我们的结果表明,抗β-纤维蛋白合成肽阳性患者的HLA-DRB1共享表位(SE)百分比高于阴性患者。我们还观察到,SE等位基因的存在与更高水平的抗[Cit(376)] betafib(365-383)抗体显着相关。当分析不同的SE等位基因的影响时,我们发现QRRAA等位基因的携带者与[Cit(376)] betafib(365-383)之间呈显着正相关(赔率比3.77; CI95%:1.41-10.08)。这些结果表明抗β-纤维蛋白状态与RA患者的免疫遗传背景有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号